Pharma
Treviamet (Sitagliptin + Metformin HCl Tablets)
Combination DPP-4 inhibitor and Biguanide; 50 mg/1000 mg Sitagliptin/Metformin tablets for Type 2 Diabetes management.
Treviamet (Sitagliptin + Metformin HCl Tablets)
Treviamet is a fixed-dose combination therapy containing Sitagliptin and Metformin Hydrochloride. Sitagliptin, a DPP-4 inhibitor, increases the levels of incretin hormones to boost insulin production and lower glucagon levels. Metformin, a biguanide, reduces the amount of sugar produced by the liver and improves how the body uses insulin. This combination is indicated for adults with type 2 diabetes mellitus to help improve blood sugar control. It is intended for use in conjunction with diet and exercise. This medication is not for use in patients with type 1 diabetes or diabetic ketoacidosis. Common side effects include gastrointestinal issues such as diarrhea, nausea, and flatulence.
You May Also Like
Combination DPP-4 inhibitor and Biguanide; 50 mg/500 mg Sitagliptin/Metformin tablets for Type 2 Diabetes management.
Triple antidiabetic combo; Dapagliflozin 10 mg, Sitagliptin 100 mg, and Metformin ER 1000 mg (28 tablets) for Type 2 Diabetes.
Combination DPP-4 inhibitor and Biguanide; 50mg/500mg Vildagliptin/Metformin tablets for Type 2 Diabetes control.
Antidiabetic combination; Empagliflozin 12.5 mg and Metformin 1000 mg (28 tablets) for Type 2 Diabetes management.